Outcome of autologous hematopoietic stem cell transplantation in children and adolescents with relapsed or refractory Hodgkin's lymphoma

Pediatric Transplantation
Volkan HazarTurkish Pediatric Bone Marrow Transplantation Study Group (TPBMT-SG)

Abstract

This study evaluates the outcome of 66 pediatric patients with rrHL who underwent autoHSCT. Twenty-nine patients experienced early relapse, and 19 patients experienced late relapse. Of 18 newly diagnosed with HL, 13 were primary refractory disease and five had late responsive disease. At the time of transplantation, only 68% of the patients were chemosensitive. The majority of patients received BCNU + etoposide + ara-C + melphalan for conditioning (45/66), and peripheral blood (56/66) was used as a source of stem cells. After a median follow-up period of 39 months, 46 patients were alive. At five yr, the probabilities of OS, EFS, the relapse rate, and the non-relapse mortality rate were 63.1%, 54.3%, 36.4%, and 9.1%, respectively. The probability of EFS in chemosensitive and chemoresistant patients at five yr was 72.3% and 19%, respectively (p < 0.001). Multivariate analysis showed that chemoresistant disease at the time of transplantation was the only factor predicting limited both OS (hazard ratio = 4.073) and EFS (hazard ratio = 4.599). AutoHSCT plays an important role for the treatment of rrHL in children and adolescents, and survival rates are better for patients with chemosensitive disease at the time of transplantation.

References

Feb 11, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D L LongoV T DeVita
Mar 1, 1985·Annals of Internal Medicine·T S HermanH S Kaplan
Jan 1, 1981·American Journal of Hematology·J R KanofskyJ E Ultmann
Nov 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C D WilliamsG Meloni
Mar 10, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·K S BakerP J Bierman
Feb 24, 2001·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·J FrankovichM R Verneris
Sep 14, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·James B NachmanUNKNOWN Children's Cancer Group
Nov 16, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·YeeYie E LieskovskyRajni Agarwal
Nov 16, 2004·Journal of Pediatric Hematology/oncology·Sara StonehamUNKNOWN United Kingdom Children's Cancer Study Group
Sep 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Günther SchellongUNKNOWN DAL/GPOH
Oct 4, 2005·Pediatric Blood & Cancer·Robert S WimmerCindy L Schwartz
Jan 20, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sarah S DonaldsonMelissa M Hudson
Dec 18, 2007·Bone Marrow Transplantation·M B Bradley, M S Cairo
May 8, 2008·Current Treatment Options in Oncology·Michael R Olson, Sarah S Donaldson
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christine Mauz-KörholzDieter Körholz
Jul 20, 2010·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Richard E HarrisMitchell S Cairo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.